{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Giacchello I"],"funding":["Ministero dell'Università e della Ricerca (MUR), Italy with PRIN 2022 PNRR","Ministero dell'Università e della Ricerca (MUR), Italy with PRIN 2022","EU funding","Associazione Italiana per la Ricerca sul Cancro, AIRC, Italy","Italian Association for Cancer Research","Ministero dell’Università e della Ricerca (MUR), Italy","NextGenerationEU-MUR PNRR","Fondazione Cassa di Risparmio di Padova e Rovigo, Italy"],"pagination":["954"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11279468"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["16(7)"],"pubmed_abstract":["The limited range of available flu treatments due to virus mutations and drug resistance have prompted the search for new therapies. RNA-dependent RNA polymerase (RdRp) is a heterotrimeric complex of three subunits, i.e., polymerase acidic protein (PA) and polymerase basic proteins 1 and 2 (PB1 and PB2). It is widely recognized as one of the most promising anti-flu targets because of its critical role in influenza infection and high amino acid conservation. In particular, the disruption of RdRp complex assembly through protein-protein interaction (PPI) inhibition has emerged as a valuable strategy for discovering a new therapy. Our group previously identified the 3-cyano-4,6-diphenyl-pyridine core as a privileged scaffold for developing PA-PB1 PPI inhibitors. Encouraged by these findings, "],"journal":["Pharmaceutics"],"pubmed_title":["Exploring a New Generation of Pyrimidine and Pyridine Derivatives as Anti-Influenza Agents Targeting the Polymerase PA-PB1 Subunits Interaction."],"pmcid":["PMC11279468"],"funding_grant_id":["PE00000007","P20222YKP8","55777 2020.0162","20223RYYFC","25899"],"pubmed_authors":["Mori M","Musumeci F","Schenone S","Carbone A","Cianciusi A","Francesconi V","Giacchello I","Bertagnin C","Loregian A","Bonomini A"],"additional_accession":[]},"is_claimable":false,"name":"Exploring a New Generation of Pyrimidine and Pyridine Derivatives as Anti-Influenza Agents Targeting the Polymerase PA-PB1 Subunits Interaction.","description":"The limited range of available flu treatments due to virus mutations and drug resistance have prompted the search for new therapies. RNA-dependent RNA polymerase (RdRp) is a heterotrimeric complex of three subunits, i.e., polymerase acidic protein (PA) and polymerase basic proteins 1 and 2 (PB1 and PB2). It is widely recognized as one of the most promising anti-flu targets because of its critical role in influenza infection and high amino acid conservation. In particular, the disruption of RdRp complex assembly through protein-protein interaction (PPI) inhibition has emerged as a valuable strategy for discovering a new therapy. Our group previously identified the 3-cyano-4,6-diphenyl-pyridine core as a privileged scaffold for developing PA-PB1 PPI inhibitors. Encouraged by these findings, ","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jul","modification":"2026-04-08T18:59:17.873Z","creation":"2025-04-19T11:30:42.919Z"},"accession":"S-EPMC11279468","cross_references":{"pubmed":["39065650"],"doi":["10.3390/pharmaceutics16070954"]}}